Prostate Cancer Drug Gets Lukewarm Review

(3 stars)
This story does a good job discussing the debate around whether federal funds should pay for this emerging prostate cancer treatment, but it failed in taking a critical look at the evidence, ultimately leaving readers with more certainty about the benefits of Provenge than the evidence warrants.